Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
Other Sizes |
|
Targets |
IC50: ~30 μM (KATP)
|
---|---|
ln Vitro |
The protective effect of penehyclidine hydrochloride (PHC) pretreatment on anoxia/reoxygenation (A/R)-induced H9c2 cell damage was eliminated by 5-Hydroxydecanoate (5-HD) treatment. 5-Hydroxydecanoate inhibits PHC's inhibitory action on ROS generation and Ca2+ overload. 5-Hydroxydecanoate encourages Cyt-C to be released into the cytoplasm from mitochondria. 5. Hydroxydecanoate reduces PHC's anti-apoptotic activity. Following PHC treatment, there was a notable rise in Bcl-2 levels and a significant drop in Bax and cleaved caspase-3 levels. 5. Pretreatment with hydroxydecanoate may counteract the impact of PHC on its expression level. Five-hydroxydecanoate inhibits PHC's impact on KATP channels [1].
|
ln Vivo |
5-Hydroxydecanoate (100 μM) therapy prevented the effects of ischemia preconditioning (IPC) on contractile recovery in rats, while leaving intact its effects on contracture, lactate generation, glycogenolysis, and viable tissue [3].
|
References |
[1]. Congna Zi, et al. Penehyclidine hydrochloride protects against anoxia/reoxygenation injury in cardiomyocytes through ATP-sensitive potassium channels, and the Akt/GSK-3β and Akt/mTOR signaling pathways. Cell Biol Int. 2020 Jun;44(6):1353-1362.
[2]. Xiantao Li, et al. 5-Hydroxydecanoate and coenzyme A are inhibitors of native sarcolemmal KATP channels in inside-out patches. Biochim Biophys Acta. 2010 Mar;1800(3):385-91. [3]. M G Marina Prendes, et al. Effects of 5-hydroxydecanoate and ischemic preconditioning on the ischemic-reperfused heart of fed and fasted rats. J Physiol Biochem. 2005 Sep;61(3):447-56. |
Molecular Formula |
C10H20O3.NA
|
---|---|
Molecular Weight |
211.2538
|
CAS # |
71186-53-3
|
Appearance |
Solid powder
|
SMILES |
CCCCCC(CCCC(=O)[O-])O.[Na+]
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 12.5 mg/mL (59.45 mM)
H2O: 10 mg/mL (47.56 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (5.95 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.25 mg/mL (5.95 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (5.95 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 6.25 mg/mL (29.73 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.7337 mL | 23.6686 mL | 47.3373 mL | |
5 mM | 0.9467 mL | 4.7337 mL | 9.4675 mL | |
10 mM | 0.4734 mL | 2.3669 mL | 4.7337 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.